In July 2023, the EMA initiated an inquiry into safety concerns after receiving approximately 150 spontaneous reports indicating potential links between drugs and suicide ideation or self-harm [72]
The order mandates attorneys to submit documentation identifying the funding company, loan amount, interest rate, fees, and repayment terms
Although the FDA officially removed tirzepatide from the shortage list in December 2024 and semaglutide in February 2025, compounded prescribing has not abated
GLP-1 + GIP Combination Medications GLP-1 + GIP combination medications act on more than one metabolic signaling pathway and may be included in a medical weight loss program for patients whose evaluation supports this approach
Methylene blue: A pharmacological and clinical overview
In January 2024, three months after taking 0.15 mg of Mounjaro, the patient reported regular migraine occurrence, and shoulder, hip, and body pain